Literature DB >> 30449805

Infectious Aneurysm Caused by Citrobacter koseri in an Immunocompetent Patient.

Takahiro Ando1, Satoshi Noguchi1, Takako Enokida1, Azusa Yamato1, Hidenori Kage1, Yasuhiro Yamauchi1, Aiko Okazaki2, Yoshitaka Wakabayashi2, Kyoji Moriya2, Haruo Yamauchi3, Minoru Ono3, Takahide Nagase1.   

Abstract

Citrobacter species can cause severe infection in immunocompetent patients. A 78-year-old man visited our hospital because he had had a fever lasting one day each month for the past 3 months. Antibiotics were initiated for suspected bronchial pneumonia, but the C-reactive protein level remained high. Contrast-enhanced computed tomography revealed saccular brachiocephalic artery aneurysm. Citrobacter koseri was isolated from a blood culture, and he was diagnosed with infectious brachiocephalic artery aneurysm. He underwent endovascular aneurysm repair after one month of intravenous cefepime and metronidazole. We herein report for the first time an immunocompetent patient with infectious aneurysm caused by C. koseri periodontal infection.

Entities:  

Keywords:  Citrobacter koseri; bloodstream infection; endovascular aneurysm repair; infectious aneurysm; periodontal disease

Mesh:

Year:  2018        PMID: 30449805      PMCID: PMC6465028          DOI: 10.2169/internalmedicine.1806-18

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Citrobacter species, which are ubiquitous Gram-negative bacilli, are considered to have low virulence and rarely cause infection in humans. While the organism usually infects immunocompromised patients, patients can contract Citrobacter without underlying disease (1,2). The organism may infect the urinary tract, gastrointestinal tract, respiratory tract, and wounds and result in bacteremia. Infectious aneurysms are rare and are reported to account for 0.7% to 3.4% of aneurysms (3,4). Infected aneurysms can rupture and become life-threatening. Gram-negative rods have been reported to be associated with a higher rate of rupture and mortality than other bacteria (5). We herein report an immunocompetent patient with infectious aneurysm caused by Citrobacter koseri periodontal infection who was treated with antibiotic therapy combined with endovascular aneurysm repair.

Case Report

A 78-year-old man visited our hospital because he had had a fever lasting one day each month for the past 3 months and was suspected of having aspiration bronchitis. Despite treatment with ampicillin-clavulanate (375 mg three times daily) for 7 days, his symptoms did not improve, and he was admitted to our hospital for a further investigation. He had periodontal disease, for which he was had been receiving ongoing treatment for four months before admission. He had no history of diabetes mellitus or hypertension. He had smoked 30 cigarettes daily for 55 years and had hypoxemia on exertion due to chronic obstructive pulmonary disease (COPD). He was taking loxoprofen (60 mg twice daily) for back pain and dental pain. On admission, his vital signs were as follows: blood pressure of 122/68 mmHg, heart rate of 88/min, respiratory rate of 18/min, percutaneous oxygen saturation values of 96% at room air, and body temperature of 38.0℃. Crackles in the left lower lung on auscultation and clubbed fingers were observed. The rest of his examination findings were normal. His laboratory data indicated white blood cells 10,200/μL, neutrophils 74%, C-reactive protein 11.1 mg/dL, and procalcitonin 0.15 mg/dL. Treponema pallidum and human immunodeficiency virus screening test findings were negative. C. koseri was isolated from a sputum bacterial culture (M1 by Miller and Jones sputum classification), while an acid-fast bacterial culture and blood culture collected on the first hospital day were negative. C. koseri was not isolated from urine or stool cultures. Chest X-ray and chest computed tomography (CT) without contrast enhancement revealed slight infiltrates and bronchial wall thickening in the left lower lobe. Electrocardiography showed ST depression in leads II, III, and aVf. A respiratory function test showed a forced expiratory volume in 1 second (FEV1.0) of 0.93 L and a percent predicted FEV1.0 of 34.6%, which was equivalent to COPD stage III. Bronchial pneumonia was suspected, and piperacillin-tazobactam (4.5 g every 8 hours) was initiated. Although his fever improved with antibiotics, his C-reactive protein levels remained elevated. Transthoracic echocardiography performed on day 7 of hospitalization revealed a slightly decreased ejection fraction but no valve abnormalities, including vegetation. Results of laboratory tests performed on day 11 were as follows: white blood cell count, 8,100/μL; neutrophils, 73%; and C-reactive protein, 7.0 mg/dL. On day 13, whole-body contrast-enhanced CT revealed saccular brachiocephalic artery aneurysms and enhanced periarterial soft tissue (Fig. 1). Calcifications in the brachiocephalic artery and aortic wall were also detected. Infectious brachiocephalic artery aneurysm was suspected, and meropenem (1 g every 8 hours) and teicoplanin (900 mg for a day, followed by 450 mg every 24 hours) were started after 2 sets of blood cultures were collected. On day 14, Gram-negative rods grew in one of the blood culture specimens, and the organism was identified as C. koseri with the same susceptibility pattern as in the previous sputum culture (Table). Based on these findings, we diagnosed the patient with infectious brachiocephalic artery aneurysm caused by C. koseri.
Figure 1.

Contrast-enhanced CT on day 13 (A, B). A saccular brachiocephalic artery aneurysm and enhanced periarterial soft tissue are seen (arrows).

Table.

Drug Susceptibility Test.

MIC (μg/mL)Susceptibility
Ampicillin>16.0Resistant
Piperacillin/tazobactam≤ 8.0Susceptible
Cefazolin≤ 2.0Resistant
Cefmetazole≤ 2.0Resistant
Ceftriaxone≤ 1.0Susceptible
Ceftazidime≤ 2.0Susceptible
Cefepime≤ 2.0Susceptible
Meropenem≤ 1.0Susceptible
Aztreonam≤ 2.0Susceptible
Gentamicin≤ 1.0Susceptible
Amikacin≤ 8.0Susceptible
Levofloxacin≤ 1.0Susceptible

MIC: minimum inhibitory concentration

Contrast-enhanced CT on day 13 (A, B). A saccular brachiocephalic artery aneurysm and enhanced periarterial soft tissue are seen (arrows). Drug Susceptibility Test. MIC: minimum inhibitory concentration The predicted operative mortality according to logistic EuroSCORE was 32.5%, and the risk of aneurysm excision with arterial reconstruction was considered too high to perform surgery. A dental examination revealed chronic suppurative apical periodontitis of a right posterior tooth, and the tooth was extracted on day 15. Head CT angiography and magnetic resonance angiography revealed no cerebral aneurysms. Colonoscopy revealed no remarkable findings in the colon or rectum that could cause bacterial translocation. We therefore considered periodontal disease to be the cause of bacteremia and, subsequently, the infectious brachiocephalic artery aneurysm. We changed the antibiotics to cefepime (1 g every 8 hours) and metronidazole (500 mg every 12 hours) on day 26. His C-reactive protein level gradually decreased and returned to normal on day 34. A re-examination of transthoracic echocardiography on day 35 revealed no vegetation, and two sets of blood cultures collected on day 42 were found to be negative. He underwent endovascular stent graft placement at the infected brachiocephalic artery aneurysm and carotid subclavian artery bypass surgery on day 46 (Fig. 2). After the surgery, he was treated with cefepime and metronidazole for three additional weeks and discharged on day 63. At discharge, he was switched to oral levofloxacin (500 mg once daily), which he has continued indefinitely. He has since remained stable without recurrence of infection at 12 months.
Figure 2.

CT angiography before (A) and after surgery (B). The saccular brachiocephalic artery aneurysm (arrow) was repaired with an endovascular stent graft.

CT angiography before (A) and after surgery (B). The saccular brachiocephalic artery aneurysm (arrow) was repaired with an endovascular stent graft.

Discussion

C. koseri are aerobic Gram-negative bacilli found in water and soil and as normal flora of the human intestine. The virulence of Citrobacter species is considered to be low, but these bacteria can cause severe infection. While infection mainly occurs in immunocompromised patients, 1 report showed that 12% of patients did not have any underlying disease (1,2). Common infection sites of Citrobacter species include the urinary tract, gastrointestinal tract, respiratory tract, and wounds (1,2). Given that our patient was immunocompetent, C. koseri likely entered the bloodstream through his periodontal disease. While Citrobacter species have been reported as a rare cause of endocarditis or arteritis (6-8), to our knowledge, this is the first documented case of infectious aneurysm caused by C. koseri periodontal infection. Infectious arterial aneurysm develops as a complication of endocarditis by infection of a preexisting intimal injury, such as atherosclerotic plaque, or by primary aortic wall infection and injury. Although the frequency of infectious aneurysm caused by bacterial endocarditis is decreasing, bacterial seeding of arteries with intimal injury is a common etiology (9). While Staphylococcus aureus and Salmonella species are considered the most common pathogens, Gram-negative organisms are also associated with infection (5,10,11). In the present case, C. koseri was isolated from saliva-like sputum that contained oral bacteria. Previous reports have demonstrated that enterobacteria, such as Citrobacter species, can be found in the oral cavity and cause periodontal disease (12,13). Our patient underwent dental treatment for his periodontal disease before admission, which may have caused the bacteremia (14). In addition, he was an elderly person with a history of heavy smoking and had calcification in the aorta and brachiocephalic artery. The aneurysm may have developed after C. koseri entered the bloodstream because the intima was vulnerable in the brachiocephalic artery. No definitive treatment for infectious aneurysm has been established because no randomized control studies have been conducted. The current standard treatment is antibiotic therapy combined with surgical debridement and revascularization (4,15). Endovascular aneurysm repair has been reported as a less-invasive and effective treatment for infected aneurysm (16,17). A life-table analysis in 48 patients with thoracic or abdominal aortic aneurysm showed that the 2-year survival rate was 82.2±5.8% (14). In addition, the 12-month survival rate of the persistently infected group was 39.0±17.0%, and that of the healed group was 94.0±4.0% (16). Preoperative control by the administration of antibiotics for a sufficient duration is important for obtaining a good outcome. In our case, surgical therapy of the brachiocephalic artery aneurysm was considered very risky because his cardiopulmonary function was low. Therefore, he was treated with endovascular aneurysm repair with preoperative antibiotics for 46 days. The optimum duration of antibiotic therapy is uncertain, but a minimum of six weeks of therapy has been widely accepted (9). In previous studies, the period of antibiotic treatments ranged from 6 weeks to lifelong (3,4,9). Cina et al. reported no marked difference in the survival or recurrence rate between lifelong therapy and therapy for 6 weeks to 12 months (4). However, the lifelong use of antibiotics can lead to an increased risk of bacterial resistance or side effects, depending on the type of antibiotics. Our patient tolerated levofloxacin and has been stable without recurrence for 12 months of antibiotics therapy. Close follow-up is considered important, as recurrence after discontinuation of antibiotic therapy has been reported (4). In conclusion, we herein report the first case of infectious aneurysm caused by C. koseri in an immunocompetent patient. He was successfully treated with antibiotic therapy combined with endovascular aneurysm repair.

The authors state that they have no Conflict of Interest (COI).
  17 in total

Review 1.  Ruptured mycotic thoracoabdominal aortic aneurysms: a report of three cases and a systematic review.

Authors:  C S Cinà; G O Arena; A O Fiture; C M Clase; B Doobay
Journal:  J Vasc Surg       Date:  2001-04       Impact factor: 4.268

Review 2.  The oral cavity as a reservoir of bacterial pathogens for focal infections.

Authors:  R Gendron; D Grenier; L Maheu-Robert
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

3.  Citrobacter infections in a tertiary care hospital in Northern India.

Authors:  Srujana Mohanty; Ritu Singhal; Seema Sood; Benu Dhawan; Arti Kapil; Bimal K Das
Journal:  J Infect       Date:  2006-06-30       Impact factor: 6.072

4.  Citrobacter diversus endocarditis.

Authors:  I Tellez; G S Chrysant; I Omer; W E Dismukes
Journal:  Am J Med Sci       Date:  2000-12       Impact factor: 2.378

5.  Experience with infected aneurysms of the abdominal aorta.

Authors:  F Jarrett; R C Darling; E D Mundth; W G Austen
Journal:  Arch Surg       Date:  1975-11

6.  Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation.

Authors:  Lone Forner; Tove Larsen; Mogens Kilian; Palle Holmstrup
Journal:  J Clin Periodontol       Date:  2006-06       Impact factor: 8.728

7.  Periodontal disease as reservoir for multi-resistant and hydrolytic enterobacterial species.

Authors:  M O Gonçalves; W P Coutinho-Filho; F P Pimenta; G A Pereira; J A A Pereira; A L Mattos-Guaraldi; R Hirata
Journal:  Lett Appl Microbiol       Date:  2007-05       Impact factor: 2.858

8.  Management of infected aortoiliac aneurysms.

Authors:  D J Reddy; A D Shepard; J R Evans; D J Wright; R F Smith; C B Ernst
Journal:  Arch Surg       Date:  1991-07

9.  Evolution of bacterial arteritis into a mycotic aortic aneurysm.

Authors:  Sachin V Phade; Dorian deFreitas; Charles S Powell; Michael Stoner
Journal:  Vasc Endovascular Surg       Date:  2007 Apr-May       Impact factor: 1.089

Review 10.  Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systematic review.

Authors:  Chung-Dann Kan; Hsin-Ling Lee; Yu-Jen Yang
Journal:  J Vasc Surg       Date:  2007-10-01       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.